Biopsy Diagnostics Articles & Analysis: Older
17 news found
This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream. Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of Groningen, The Netherlands, has published research comparing the performance of the ISET technology to the reference ...
It was concluded that OCT-guided diagnosis, when compared to a standard punch biopsy could reduce the number of consultations and invasive procedures by a massive 66%. ...
Pankaj Jain at Arizona Urology said, “With our goal to offer the most advanced prostate cancer diagnostics and treatment platform, Arizona Urology is now excited to integrate the Promaxo MRI system into our practice in order to administer the best diagnostic biopsy and treatment plans to our patients. ...
” “The clinical community has received our Promaxo system with enthusiasm, as it enables safe and effective point of care diagnostic biopsies, with an open architecture facilitating treatment of cancers using various technology platforms, overcoming limitations of traditional MRIs. ...
April 25, 2022 at 9:30 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 25, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding ...
In partnering with Promaxo, we are bringing minimally invasive, office based MRI to Beverly Hills, California, with a clinical focus on MR guided biopsies and treatments such as high intensity focused ultrasound (HIFU) of the prostate ...
In clinical partnership with Promaxo, we look forward to optimizing clinical workflow for office-based MRI guided biopsies in our high volume practice, and to collaborating on prostate cancer treatments, including brachytherapy and post placement confirmatory scans of hydrogel with Promaxo's MRI ...
“Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving way for our $3 billion addressable market for in-office prostate procedures. ...
Pre-treatment Biomarker – INOVIO and QIAGEN have made progress in biomarker development by identifying candidate biomarker signatures for VGX-3100 with the intent of selecting a final signature in a pre-treatment in vitro diagnostic to improve the primary clinical outcome for biomarker-positive patients with cervical HSIL. ...
” “Promaxo has developed a proprietary system for point of care diagnostic biopsies and treatment of cancers, with a $3 billion addressable market for in-office urology procedures. We welcome the opportunity to support Promaxo as it drives a shift into in-office diagnostic and therapeutic procedures. We look forward to what the ...
The EPI-CE test will be performed immediately in our Munich ISO 15189 accredited clinical laboratory and be made available throughout Europe through various distribution channels. Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. ...
The company’s Imagio® Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may – or may not – require more invasive diagnostic evaluation. Breast biopsy procedures caused by ...
The results of these two feasibility studies demonstrate exciting new potential applications and new methods to utilize cellular level optical computed tomography (CT) and artificial intelligence (AI) of VisionGate’s 3D single cell imaging Cell-CT platform to obtain lung cancer diagnostic and biomarker information from a sputum liquid biopsy. The first ...
VisionGate is a clinical stage oncology pharmaceutical and diagnostics company focused on the early detection and prevention of cancer. ...
VisionGate is a clinical stage oncology pharmaceutical and diagnostics company focused on the early detection and prevention of cancer. ...
Nelson, PhD, Chairman and CEO in a statement. Cancer Diagnostics Services: Our initial cancer diagnostic services test, the LuCED® lung test, has been developed to support the early detection of lung cancer. ...